News and Announcements
2 x China Tender Success for FIVE2 (ViewnVivo)
- Published July 29, 2020 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OptiScan Imaging Limited (ASX: OIL) (‘the Company’ or ‘OptiScan’) is pleased to advise that its Eastern China distributor has been successful in two tenders for the sale of the FIVE2 (ViewnVivo) system. Formal orders are expected to be received next month with revenues in excess of A$350k to be received from the 2 sales. Success in these tenders brings sales to 3 since Optiscan changed its distribution arrangements in China late last year.
Executive Chairman and CEO of OptiScan, Darren Lurie, said “Since being implemented late last year, we are delighted to see the progress that our multi-distributor model for the Chinese market is making. In addition to these sales, our distributors are actively working to develop their pipeline of further sales notwithstanding the disruption caused by COVID-19 with further initiatives including webinars planned.”
About Optiscan
OptiScan (ASX:OIL) is an Australian listed company and a pioneer in the development and application of endomicroscopic imaging technologies for medical markets. Our multi-patented confocal imaging technology can be used for both cancer screening and tumour margin detection in cancer surgery. Our device enables real-time, in vivo imaging at the cellular level in clinical applications, providing a “digital” biopsy. The benefits of this “digital” biopsy include monitoring of early-stage disease, earlier identification of pre-cancer and the potential to reduce the time doctors, patients and operating theatres are required to wait for pathology results, the number of repeat surgeries and actual biopsies required.
Company Updates
The Ferrari of Immunotherapy: Chimeric’s High-Stakes Race to Cure Cancer
In the high-stakes world of biotechnology, the most sophisticated weapon against cancer isn’t a new chemical compound but the patient’s own immune system, re-engineered with the precision of a high-performance engine. “This particular CAR T is like a Ferrari,” says Dr. Rebecca McQualter, CEO of Chimeric Therapeutics (ASX: CHM). “It’s got two big engines on […]
From Algae Pioneers to a Natural Revolution: The Second Act of WRS Bioproducts
As the US FDA prepares to phase out synthetic food colors by the end of 2026, WRS Bioproducts is stepping in to solve a looming supply crisis. Led by industry pioneer Harry Rosen, the company is leveraging 40 years of industrial algae farming expertise to scale production of natural, superior-quality beta-carotene, positioning itself as a vital supplier in the rapidly shifting global market for natural ingredients.
Dying for a Cure: Why Astraea is Stress-Testing the Future of Space Medicine
Astraea Technologies is solving a critical “blind spot” in the $1.5T space economy. Co-founders Brooke Mills and Gordon Carroll discuss their $5M seed raise, the HIRO-LAB platform, and their upcoming 2028 mission to the Moon to validate life-saving medicine in extreme environments.
Backed By Leading Investment Groups and Family Offices
